

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

e Application of:

Pradier et al.

Group Art Unit: 1645

Serial No.:

08/716,209

Examiner: S. Gucker

U.S. National Stage of PCT/FR95/00250

Filed:

March 2, 1995

For:

Recombinant Adenoviruses Coding For Brain-Derived Neurotrophic Factor (BDNF)

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paula L. Dickey

(Type or print name of person mailing paper)

To:

Assistant Commissioner For Patents

Washington, D.C. 20231

Dear Sir:

NOTICE OF APPEAL FROM THE PRIMARY EXAMINER TO THE BOARD OF PATENT APPEALS AND INTERFERENCES

Applicants hereby appeal to the Board from the decision of the Primary Examiner mailed October 28, 1999, finally rejecting claims 27-28, 31-35, 37-38, 40-41 and 48-50.

The item(s) below are appropriate:

- 1. A Petition for Extension of Time to respond to the final rejection up to and including April 28, 2000, is being filed concurrently herewith;
- 2. The Notice of Appeal fee due is \$300.00;
- Please charge Deposit Account No. 18-1982 in the amount of \$300.00. Any defiency or 3. overpayment should be charged or credited to Deposit Account No. 18-1982; and
- 4. The original and two copies of this transmittal are herewith enclosed.

Dated:

Aventis Pharmaceuticals Products Inc.

April 25, 2000

P.O. Box 5093, Mailstop #3C43 Collegeville, PA 19426-0997 Telephone: (610) 454-3178 Facsimile: (610) 454-3808

Respectfully submitted,

Rachel H. Rondinelli, Ph.D. Agent for Applicants

Registration No. 45,052

00000053 161962